Introduction
============

Dual bronchodilation therapy is the cornerstone for the treatment of COPD, and a large body of evidence indicates that combining a long-acting β~2~-agonist (LABA) with a long-acting muscarinic antagonist (LAMA) leads to synergistic bronchorelaxant effect.[@b1-copd-12-3469]--[@b5-copd-12-3469] Although some fixed-dose combinations (FDCs) elicit prevalently additive interaction when administered at the concentration-ratio currently available in the market,[@b6-copd-12-3469],[@b7-copd-12-3469] the beneficial interaction between LABAs and LAMAs is a pharmacological characteristic that would allow reduction of the doses of each monocomponent in order to optimize bronchodilation and, thus, reduce the risk of adverse events (AEs).[@b8-copd-12-3469]

Unfortunately, the doses of each single bronchodilator included in the currently available LABA/LAMA FDCs have not been modified with respect to the doses of medications containing single-agents. Such an approach may appear simplistic, as it does not allow modulation of the doses of the dual bronchodilation therapy accordingly with the characteristics of COPD patients, namely clinical conditions and airflow limitation.[@b9-copd-12-3469] Furthermore, it can raise concerns with regard to the safety profile of LABA/LAMA FDCs. In fact, since both LABAs and LAMAs administered as monocomponents at the full doses approved for the treatment of COPD are burdened by the potential risk of inducing cardiovascular serious AEs (SAEs), the risk of combining an LABA with an LAMA could be even greater.[@b10-copd-12-3469]

Results of a recent meta-analysis did not show any significant difference concerning the cardiac safety profile of LABA/LAMA FDCs compared with their monocomponents.[@b11-copd-12-3469] Nevertheless, several studies were not included in that previous analysis because no suitable data on cardiac SAEs were reported,[@b11-copd-12-3469] no randomized clinical trials (RCTs) were available for all the currently approved FDCs, and the vascular safety profile was not investigated.

Since the question about the real impact of LABA/LAMA FDCs on the cardiovascular system is still open, we have carried out a pair-wise meta-analysis in order to characterize the cardiovascular safety profile and mortality of each LABA/LAMA FDC currently approved for the treatment of COPD. Furthermore, since a well-performed quantitative synthesis allows for indirect comparisons of multiple interventions that have not been studied in a head-to-head fashion,[@b12-copd-12-3469] we have also carried out a network meta-analysis in order to compare the cardiovascular safety profile of the approved LABA/LAMA FDCs.

Methods
=======

Search strategy
---------------

This pair-wise and network meta-analysis has been registered in PROSPERO (registration number: CRD42017070100; available from: <https://www.crd.york.ac.uk/PROSPERO/display_record.asp?ID=CRD42017070100>), and performed in agreement with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) Statement ([Figure 1](#f1-copd-12-3469){ref-type="fig"}).[@b13-copd-12-3469] Furthermore, this synthesis satisfied all the recommended items reported by the PRISMA-P 2015 checklist.[@b14-copd-12-3469]

We undertook a comprehensive literature search for RCTs evaluating the impact of dual bronchodilation on the risk of cardiovascular SAEs in patients suffering from COPD, diagnosed by pulmonary function testing.

The LABA/LAMA FDCs currently approved in COPD by the European Medicines Agency and/or US Food and Drug Administration were searched. In particular, aclidinium/formoterol 400/12 µg (A/F 400/12), glycopyrronium/indacaterol 15.6/27.5 µg (G/I 15.6/27.5), glycopyrronium/indacaterol 50/110 µg (G/I 50/110), umeclidinium/vilanterol 62.5/25 µg (U/V 62.5/25), tiotropium/olodaterol 5/5 µg (T/O 5/5), and glycopyrronium/formoterol 14.9/9.6 µg (G/F 14.4/9.6) were searched for the FDCs, and the terms "chronic obstructive pulmonary disease" and/or "COPD" were searched for the disease. The search was performed in PubMed, Scopus, Embase, Google Scholar and the repository database [ClinicalTrials.gov](htp://ClinicalTrials.gov) through June 2017,[@b15-copd-12-3469] in order to identify relevant studies reported in English and published up to June 31, 2017. Citations of previously published meta-analyses and relevant reviews were checked to select further pertinent studies, if any.[@b10-copd-12-3469],[@b11-copd-12-3469],[@b16-copd-12-3469]--[@b18-copd-12-3469]

Two reviewers independently checked the relevant RCTs identified from literature searches and databases. RCTs were selected in agreement with the previously mentioned criteria, and any difference in opinion about eligibility was resolved by consensus.

Study selection
---------------

RCTs reporting in the repository database [ClinicalTrials.gov](http://ClinicalTrials.gov) raw data concerning the impact of the approved LABA/LAMA FDCs versus monocomponents and/or placebo on cardiovascular SAEs in COPD patients were selected, and those reporting at least one cardiovascular SAE were included in the meta-analysis. No restriction on the duration of the treatment was applied. Two reviewers independently examined the clinical trials and any difference in opinion about eligibility was resolved by consensus.

Data extraction
---------------

Data from included studies were extracted from published papers, and/or online supplementary files, and/or the public database [ClinicalTrials.gov](http://ClinicalTrials.gov). Data extraction was carried out in agreement with the recommendations provided by the Cochrane Handbook for Systematic Reviews of Interventions.[@b19-copd-12-3469] Data were extracted and checked for study characteristics and duration, doses of medications, patient characteristics, age, gender, smoking habits, forced expiratory volume in 1 second (FEV~1~), cardiovascular SAEs, and Jadad score.

Endpoints
---------

The primary endpoint of this quantitative synthesis was to assess the cardiovascular safety profile (SAEs) of LABA/LAMA FDCs administered at the currently approved doses in COPD patients, compared with the monocomponents included in the FDCs.

The secondary endpoints were, 1) the influence of the currently approved LABA/LAMA FDCs on mortality in COPD patients, compared with the monocomponents included in the FDCs, and 2) the indirect safety comparison on cardiovascular SAEs among the currently approved LABA/LAMA FDCs compared with placebo.

Quality score, risk of bias and evidence profile
------------------------------------------------

The Jadad score, with a scale of 1--5 (score of 5 being the best quality), was used to assess the quality of the RCTs concerning the likelihood of biases related to randomization, double-blinding, withdrawals and dropouts.[@b11-copd-12-3469] Two reviewers independently assessed the quality of individual studies, and any difference in opinion about the quality score was resolved by consensus.

The risk of publication bias was assessed by applying the funnel plot and Egger's test through the following regression equation: SND = a+b × precision, where SND represents the standard normal deviation (treatment effect divided by its standard error \[SE\]), and precision represents the reciprocal of the SE. Evidence of asymmetry from Egger's test was considered to be significant at *P*\<0.1, and the graphical representation of 90% confidence bands are presented.[@b11-copd-12-3469]

The optimal information size (OIS) was calculated as previously described[@b20-copd-12-3469] and the quality of the evidence has been assessed in agreement with the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) system.[@b21-copd-12-3469]

Data analysis
-------------

We performed both a pair-wise and network meta-analysis to evaluate the cardiovascular safety profile of LABA/LAMA FDCs in COPD patients. Since the follow-up duration was not consistent among the RCTs included in this meta-analysis, the data have been normalized as a function of person-year.[@b22-copd-12-3469]--[@b24-copd-12-3469] This method involved the conversion of the measures into a common metric (events per person-time) prior to meta-analysis of the data, leading to increased estimates of effect, precision, and clinical interpretability of results.[@b19-copd-12-3469],[@b25-copd-12-3469]

Results are expressed as Risk Ratio (RR) and 95% CI in pair-wise meta-analysis. Since data were selected from a series of studies performed by researchers operating independently, and a common effect size cannot be assumed, we used the random-effects model to perform the pair-wise meta-analysis in order to balance the study weights and adequately estimate the 95% CI of the mean distribution of drugs effect on the investigated variable.[@b22-copd-12-3469] In fact, although the mathematics behind the fixed-effects model are much simpler than those of the random-effects model, results of this quantitative synthesis cannot be generalized via fixed-effects model since the included studies were quite dissimilar,[@b26-copd-12-3469] as reported in [Table 1](#t1-copd-12-3469){ref-type="table"}. Therefore, the greater the degree of difference among the studies incorporated in the analysis, the more important it becomes to employ the random-effects model.[@b27-copd-12-3469]

Subset analyses were performed with regard to the effect of the class of monocomponents included in the FDCs (LABAs or LAMAs) and each specific FDC. High quality studies were identified as having Jadad score ≥3.[@b28-copd-12-3469]

The network meta-analysis was performed to indirectly compare the effect of specific FDCs. A full Bayesian evidence network was used (chains: 4; initial values scaling: 2.5; tuning iterations: 20,000; simulation iterations: 50,000; tuning interval: 10), and the convergence diagnostics for consistency and inconsistency were assessed via the Brooks--Gelman--Rubin method, as previously reported.[@b29-copd-12-3469] Due to the characteristics of parameters besides the available data, the just proper non-informative distributions specified the prior densities, in agreement with the Bayesian Approaches to Clinical Trials and Health-Care Evaluation.[@b30-copd-12-3469],[@b31-copd-12-3469] Since the distributions were sufficiently vague, the reference treatment, study baseline effects, and heterogeneity variance were unlikely to have a noticeable impact on model results. In this condition, GeMTC software automatically generates and runs the required Bayesian hierarchical model and selects the prior distributions and starting values as well, via heuristically determining a value for the outcome scale parameter (ie, outcome scale S).[@b32-copd-12-3469],[@b33-copd-12-3469] The posterior mean deviance of data points in the unrelated mean effects model was plotted against the posterior mean deviance in the consistency model in order to provide information for identifying the loops in the treatment network where evidence was inconsistent.[@b34-copd-12-3469] Results of the network meta-analysis are expressed as relative effect and 95% credible level. The probability that each intervention arm was the most effective was calculated by counting the proportion of iterations of the chain in which each intervention arm had the highest mean difference, and the surface under the cumulative ranking curve (SUCRA), representing the summary of these probabilities, was also calculated. The SUCRA is 100% when a treatment is certain to be the best, and 0% when a treatment is certain to be the worst.[@b29-copd-12-3469]

OpenMetaAnalyst (open-source, software for advanced pair-wise meta-analysis, available at <http://www.cebm.brown.edu/openmeta/index.html>) and GeMTC (open-source, software for advanced network meta-analysis, available at <https://gemtc.drugis.org>) were used for performing the meta-analysis, GraphPad Prism (GraphPad Software, La Jolla, CA, US) software to graph the data, and GRADEpro GDT (GRADEpro Guideline Development Tool. McMaster University, Hamilton, Canada, 2015, developed by Evidence Prime, Inc. Available at [gradepro.org](http://gradepro.org)) to assess the quality of evidence.[@b21-copd-12-3469],[@b32-copd-12-3469],[@b35-copd-12-3469] The statistical significance was assessed for *P*\<0.05, and moderate-to-high levels of heterogeneity were considered for *I*^2^\>50%.

Results
=======

Studies characteristics
-----------------------

Results obtained from 26,650 COPD patients (19,157 treated with an FDC, 7,197 treated with an LABA, 5,990 treated with an LAMA, and 4,306 treated with placebo) were selected from 23 studies, including 29 RCTs: four on A/F 400/12 FDC,[@b36-copd-12-3469]--[@b39-copd-12-3469] two on G/I 15.6/27.5 FDC,[@b40-copd-12-3469] four on G/I 50/110 FDC,[@b41-copd-12-3469]--[@b44-copd-12-3469] nine on T/O 5/5 FDC,[@b45-copd-12-3469]--[@b50-copd-12-3469] seven on U/V 62.5/25 FDC,[@b6-copd-12-3469],[@b51-copd-12-3469]--[@b55-copd-12-3469] and three on G/F 14.4/9.6.[@b56-copd-12-3469],[@b57-copd-12-3469] All RCTs were randomized and blinded, were published between 2013 and 2017, the period of treatment ranged from 2 to 64 weeks, and they were characterized by a Jadad score ≥3. Overall, the inclusion criteria and population characteristics of the analyzed studies were homogeneous. More details on studies characteristics are reported in [Table 1](#t1-copd-12-3469){ref-type="table"}.

Pair-wise meta-analysis
-----------------------

### Impact of LABA/LAMA FDCs on cardiovascular SAEs

Raw data concerning the cardiovascular disorders that occurred during the RCTs have been extracted from the SAEs files of the [ClinicalTrials.gov](http://ClinicalTrials.gov) database. All studies reported suitable data on cardiovascular safety.

The overall pair-wise meta-analysis indicated that LABA/LAMA FDCs did not significantly (*P*\>0.05) modulate the risk of cardiovascular SAEs in COPD patients, compared with respective monocomponents (FDCs versus monocomponents: RR 0.94, 95% CI 0.79--1.13, *I*^2^ 0%; FDCs versus LABAs: RR 0.98, 95% CI 0.72--1.34, *I*^2^ 9%; FDCs versus LAMAs: RR 0.90, 95% CI 0.71--1.13, *I*^2^ 0%) ([Figure 2A](#f2-copd-12-3469){ref-type="fig"}). The subset analysis on specific FDCs showed a signal (*P*=0.077) of protection against cardiovascular SAEs for A/F 400/12 versus monocomponents (RR 0.61, 95% CI 0.35--1.06, *I*^2^ 0%), whereas a significant (*P*\<0.05) risk was detected for G/F 14.4/9.6 versus monocomponents (RR 1.36, 95% CI 1.00--1.85, *I*^2^ 0%). G/I 15.6/27.5, G/I 50/110 FDC, U/V 62.5/25, and T/O 5/5 FDCs had no significant (*P*\>0.05) impact on cardiovascular safety ([Figure 2B](#f2-copd-12-3469){ref-type="fig"}).

In any case, the pooled analysis indicated that 34.88% of cardiovascular SAEs occurred with rare frequency (≥1/10,000 to \<1/1,000) and 14.20% with uncommon frequency (≥1/1,000 to \<1/100), whereas for 50.93% of cardiovascular SAEs, the frequency could not be estimated from the available data.

The three most frequent cardiovascular SAEs were atrial fibrillation (overall: 0.39%), myocardial infarction (overall: 0.27%), and coronary artery disease (overall: 0.26%), with no difference among LABA/LAMA FDCs, monocomponents and placebo. Details on the frequency of specific cardiovascular SAEs are reported in [Table 2](#t2-copd-12-3469){ref-type="table"}.

### Impact of LABA/LAMA FDCs on mortality

LABA/LAMA FDCs did not significantly (*P*\>0.05) influence the risk of death in COPD patients, compared with respective monocomponents (FDCs versus monocomponents: RR 0.89, 95% CI 0.51--1.56, *I*^2^ 0%; FDCs versus LABAs: RR 0.87, 95% CI 0.38--1.98, *I*^2^ 9%; FDCs versus LAMAs: RR 0.91, 95% CI 0.43--1.95, *I*^2^ 0%). No impact on the risk of death was detected for each specific FDC (*P*\>0.05 versus monocomponents).

Network meta-analysis
---------------------

The ranking plot resulting from the network meta-analysis identified three distinct clusters of safety with regard to the risk of cardiovascular SAEs. Specifically, A/F 400/12 and T/O 5/5 were the safest FDCs, followed by U/V 62.5/25 which showed a safety profile similar to that of placebo, whereas G/F 14.4/9.6, G/I 15.6/27.5, and G/I 50/110 were the least safe FDCs ([Figure 3](#f3-copd-12-3469){ref-type="fig"}). The SUCRA values of the cardiovascular safety profile are reported in [Table 3](#t3-copd-12-3469){ref-type="table"}.

Bias and quality of evidence
----------------------------

No heterogeneity was detected in the pair-wise meta-analysis, and the consistency/inconsistency analysis of the network meta-analysis indicated that all the points fitted adequately with the line of equality (*R*^2^ 0.99; slope 1.02).

Overall, this meta-analysis met a reasonable OIS to ensure a very good (probability of observing 30% overestimation for τ^2^=0.25: \<1% at true relative risk reduction 10%) to excellent (probability of observing 20% overestimation for τ^2^=0.05: \<1% at true relative risk reduction 0%) low risk of observing an overestimated intervention effect due to random errors.

The analysis of bias carried out via the visual inspection of the funnel plot evidenced neither dispersion nor asymmetry ([Figure 4A](#f4-copd-12-3469){ref-type="fig"}), whereas Egger's tests indicated that smaller studies might have weakly, although significantly (asymmetry coefficient: 0.071±0.068; *P*\<0.1), distorted the results of this meta-analysis by inducing a greater effect estimate ([Figure 4B](#f4-copd-12-3469){ref-type="fig"}). The GRADE approach indicated high quality of evidence (⊕⊕⊕⊕) for the safety profile of LABA/LAMA FDCs in COPD patients resulting from this meta-analysis.

Discussion
==========

The findings of this quantitative synthesis indicate that the LABA/LAMA FDC is a safe therapeutic approach in COPD patients. The safety profile resulting from the pair-wise meta-analysis shows that combining an LABA with an LAMA does not amplify the potential cardiovascular SAEs that characterized the LABAs and LAMAs when administered as monocomponents. This result is confirmed by the subgroup analysis performed on the specific LABA/LAMA FDCs, namely G/I 15.6/27.5, G/I 50/110, U/V 62.5/25 and T/O 5/5, but not for A/F 400/12 and G/F 14.4/9.6. In particular, A/F 400/12 provided a strong signal of protection against cardiovascular SAEs compared with monocomponents, whereas a higher risk of cardiovascular SAEs was detected for G/F 14.4/9.6.

Therefore, in order to better characterize the safety profile of the LABA/LAMA FDCs at the currently approved doses, we also performed a network meta-analysis using the placebo arm as the common intervention among the RCTs included in this study. Such a network approach allowed us to perform an indirect comparison of the investigated interventions that were not previously studied in a head-to-head fashion.[@b12-copd-12-3469] Results of the network meta-analysis generally confirm those of the pair-wise meta-analysis. The risk of cardiovascular SAEs was lower in COPD patients treated with A/F 400/12 and T/O 5/5 FDCs than in the placebo arm, it was similar to placebo for U/V 62.5/25 FDCs, and higher than placebo for G/F 14.4/9.6, G/I 15.6/27.5, G/I 50/110 FDCs.

Indeed, the network meta-analysis would provide more refined estimates if data on direct comparison between LABA/LAMA FDCs were available but, unfortunately, results on head-to-head RCTs are not currently available. However, studies comparing U/V with T/O and G/F with U/V are ongoing ([ClinicalTrials.gov](http://ClinicalTrials.gov) identifiers: NCT02799784 and NCT03162055, respectively), and two further RCTs aiming to compare G/I with U/V have been completed but study results have not yet been posted ([ClinicalTrials.gov](http://ClinicalTrials.gov) identifiers: NCT02487498 and NCT02487446). When these results are accessible to independent researchers, closed loops might be created into the network to further improve the consistency of the indirect comparisons.[@b58-copd-12-3469]

In any case, we have to recognize that, although a rank of safety profile exists among the LABA/LAMA FDCs, no difference on the risk of death was detected for each specific FDC. Furthermore, mortality was detected with the same uncommon frequency in COPD patients receiving LABA/LAMA FDCs as in those treated with monocomponents and placebo. Similarly, the most frequent cardiovascular SAE, atrial fibrillation, had the same frequency among the treatments, including placebo, with the highest value of \<4 cases in 1,000 patients.

From a strictly analytical point of view, the detected rare/uncommon frequency of cardiovascular SAEs makes it difficult to get concordant results and, since there is no perfect meta-analysis technique for low frequency events, the findings on statistical significance or signal of significance must be interpreted cautiously.[@b59-copd-12-3469],[@b60-copd-12-3469] In fact, although this quantitative synthesis provides a high quality of evidence, we have detected a certain level of bias related with the so-called "small study effect", leading to a higher risk of cardiovascular SAEs in smaller RCTs compared with that observed in larger studies. This bias, together with the fact that few studies have been performed on the G/F 14.4/9.6 FDC, may have caused an imbalance in the effect estimates in favour of A/F 400/12 and against G/F 14.4/9.6 FDCs.

Furthermore, we cannot exclude that the occurrence of rare/uncommon cardiovascular SAEs may be related to various features of the individual patient. Although the safety profile is an essential element for approval by regulatory authorities, pivotal RCTs include a small and highly selected fraction of the patients. Indeed, the populations selected for RCTs only partially represent the real-life population, as it has been extensively proved that in large populations of individuals with an established diagnosis of COPD fewer than ∼−14% of outpatients were eligible for inclusion in RCTs.[@b61-copd-12-3469],[@b62-copd-12-3469] In particular, COPD patients with co-morbidities are usually excluded from RCTs, and this approach may lead to potential bias considering that COPD is a risk factor for several cardiovascular diseases.[@b10-copd-12-3469] In this regard, post-marketing surveillance and observational studies represent useful tools to adequately assess the safety profile of LABA/LAMA FDCs in the real-life population of COPD patients.[@b63-copd-12-3469]

The rank of cardiovascular safety detected in this meta-analysis may also be explained by considering the dissimilarities in the pharmacodynamic and pharmacokinetic characteristics of the individual components of any LABA/LAMA FDC. Indeed, the cardiovascular AEs are due to absorption and systemic distribution of LABAs and LAMAs after inhalation.[@b64-copd-12-3469] The localization of β~2~-adrenergic receptor (AR) agonist in the heart modulates the cardiac functions, although the heart expresses a lower β~2~-AR density than do the airways. Therefore, full (ie, formoterol, indacaterol) or near-full β~2~-AR agonists (ie, olodaterol) would have a greater cardiac impact than partial agonists (ie, vilanterol).[@b65-copd-12-3469],[@b66-copd-12-3469] However, it is well known that desensitization through dampening of the signaling cascade or down-regulation of the number of β~2~-ARs (ie, tachyphylaxis) after chronic β~2~-AR agonist use might often resolve the reported side effects such as tachycardia as seen on treatment initiation.[@b64-copd-12-3469]

Also, the blockade of the M~2~ muscarinic receptor induced by LAMAs has the potential to cause cardiovascular AEs. However, LAMAs are characterized by important differences in dissociation half-lives for muscarinic antagonists against the M~2~ and M~3~ muscarinic receptor subtypes.[@b67-copd-12-3469] In particular, glycopyrronium and umeclidinium are characterized by a greater selectivity for the M~3~ muscarinic receptor versus the M~2~ muscarinic receptor compared with tiotropium, and dissociate from the M~2~ muscarinic receptor more readily than does tiotropium.[@b68-copd-12-3469],[@b69-copd-12-3469] Aclidinium is rapidly hydrolyzed into derivatives that are devoid of any affinity for all muscarinic receptor subtypes.[@b10-copd-12-3469],[@b70-copd-12-3469]

It is intriguing that in this meta-analysis, FDCs, including glycopyrronium combined with two full/nearly full β~2~-AR agonists (fromoterol and indacaterol) exhibited a higher risk for cardiovascular SAEs than placebo. A comprehensive analysis of clinical studies and post-marketing data has already shown that atrial fibrillation events were seen more often with glycopyrronium than with placebo, although the difference was not statistically significant.[@b71-copd-12-3469]

The aforementioned analysis,[@b71-copd-12-3469] and the rare/uncommon frequency of cardiovascular SAEs detected in the present meta-analysis, suggest that there may be a different cardiovascular response to muscarinic receptors blockage and β~2~-ARs stimulation in individual patients, that is not specific to any LAMA or LABA. It has been suggested that rare polymorphisms in regulator of G-protein signaling 2, a putative regulator of the M~3~ muscarinic receptor, can be associated with arrhythmias.[@b72-copd-12-3469] Furthermore, there is evidence that M~3~ muscarinic receptor overexpression reduces the incidence of arrhythmias and mortality in a mouse model of myocardial ischemia--reperfusion, by protecting the myocardium from ischemia.[@b73-copd-12-3469] It is likely that changes in this overexpression on an individual basis may induce different responses to the blockade of muscarinic receptors operated by muscarinic antagonists, considering that all of the muscarinic antagonists can cause more or less cardiovascular SAEs.[@b74-copd-12-3469],[@b75-copd-12-3469] On the other hand, patients who are less susceptible to desensitization, due to different genetic variants of the β~2~-AR, are more likely to be at a higher risk of cardiovascular SAEs, particularly in individuals with long-term exposure to accumulated doses of β~2~-AR agonist.[@b76-copd-12-3469],[@b77-copd-12-3469] Unfortunately, the examined RCTs were not focused on genetic variations and, consequently, patients were not stratified according to genotype. Nonetheless, we do not believe that a specific LABA/LAMA FDC may expose patients to higher risks of real SAEs than do other FDCs. Rather, we believe that there may be a different cardiovascular response to any LABA/LAMA FDC in individual patients. Therefore, it will be essential to make all possible efforts to proactively identify patients at increased risk of cardiovascular SAEs when treated with LABA/LAMA FDCs.

Finally, but not less important, also the drug formulations and the characteristics of the specific devices, that can influence the systemic drug concentrations, may have an impact on the possible occurrence of cardiovascular SAEs, and lead to potential imbalance of the safety profile in favor of some LABA/LAMA FDCs rather than others.[@b78-copd-12-3469],[@b79-copd-12-3469]

Conclusions
===========

This quantitative synthesis provides high quality evidence that LABA/LAMA FDC therapy is characterized by an excellent cardiovascular safety profile, at least in the COPD population enrolled in RCTs. The rare/uncommon frequency of cardiovascular SAEs suggests that the rank of safety profile across the currently approved LABA/LAMA FDCs should be interpreted with caution, and results considered exploratory in nature and hypothesis-generating.[@b60-copd-12-3469] Although the choice of a specific LAMA/LABA FDC should not be based on any difference in the safety profile, post-marketing surveillance and observational studies may help to better define the real impact of specific LABA/LAMA FDCs with regard to the cardiovascular risk.
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![PRISMA flow diagram for the identification of studies included in the meta-analysis concerning the impact of LABA/LAMA FDCs on cardiovascular SAEs in COPD patients.\
**Abbreviations:** COPD, chronic obstructive pulmonary disease; FDCs, fixed-dose combinations; LABAs, long-acting β~2~-agonists; LAMAs, long-acting muscarinic antagonists; PK, pharmacokinetic; RCT, randomized controlled trial; SAEs, serious adverse events.](copd-12-3469Fig1){#f1-copd-12-3469}

###### 

Forest plot of pair-wise meta-analysis of the impact of the LABA/LAMA FDCs on cardiovascular SAEs in COPD patients.

**Note:** Overall analysis performed by comparing LABA/LAMA FDCs versus LABAs or LAMAs (**A**), and subset analysis considering each specific FDC versus monocomponents (**B**).

**Abbreviations:** A, aclidinium; COPD, chronic obstructive pulmonary disease; F, formoterol; FDCs, fixed-dose combinations; G, glycopyrronium; I, indacaterol; LABAs, long-acting β~2~-agonists; LAMAs, long-acting muscarinic antagonists; O, olodaterol; SAEs, serious adverse events; T, tiotropium; U, umeclidinium; V, vilanterol.
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![Ranking plot of the network on the cardiovascular safety profile of LABA/LAMA FDCs versus placebo in COPD patients.\
**Note:** Treatments have been plotted on the X-axis according to SUCRA (score of 1 being the safest) and on the Y-axis according to the rank of being the best treatment (score of 1 being the safest).\
**Abbreviations:** A, aclidinium; COPD, chronic obstructive pulmonary disease; F, formoterol; FDC, fixed-dose combination; G, glycopyrronium; I, indacaterol; LABA, long-acting β~2~-agonist; LAMA, long-acting muscarinic antagonists; O, olodaterol; PCB, placebo; SUCRA, surface under the cumulative ranking curve; T, tiotropium; U, umeclidinium; V, vilanterol.](copd-12-3469Fig3){#f3-copd-12-3469}

![Publication bias assessment via funnel plot (**A**) and Egger's test (**B**) for the impact of LABA/LAMA FDCs on cardiovascular SAEs in COPD patients, versus respective monocomponents.\
**Note:** \**P*\<0.1.\
**Abbreviations:** A, aclidinium; COPD, chronic obstructive pulmonary disease; F, formoterol; FDCs, fixed-dose combinations; G, glycopyrronium; I, indacaterol; LABA, long-acting β~2~-agonist; LAMA, long-acting muscarinic antagonists; O, olodaterol; OR, odds ratio; SAEs, serious adverse events; SND, standard normal deviate; T, tiotropium; U, umeclidinium; V, vilanterol.](copd-12-3469Fig4){#f4-copd-12-3469}

###### 

Patient demographics, baseline and study characteristics

  Study and year                              [ClinicalTrials.gov](http://ClinicalTrials.gov) identifier   Study characteristics                                                                                          Duration of study (weeks)   Number of analyzed patients   Drugs (doses)                             Inhaler device (brand)                                                  Administration regimen   Patient characteristics                                                                                                                      Age (years)   Male (%)   Current smokers (%)   Smoking history (pack-years)   Post-bronchodilator FEV~1~ (% predicted)   Jadad score
  ------------------------------------------- ------------------------------------------------------------ -------------------------------------------------------------------------------------------------------------- --------------------------- ----------------------------- ----------------------------------------- ----------------------------------------------------------------------- ------------------------ -------------------------------------------------------------------------------------------------------------------------------------------- ------------- ---------- --------------------- ------------------------------ ------------------------------------------ -------------
  D'Urzo et al (2017)[@b36-copd-12-3469]      NCT01572792                                                  Randomized, double-blind, parallel-group, placebo- and active-controlled                                       28                          714                           Aclidinium/formoterol 400/12 µg           Dry powder inhaler (Genuair^®^/Pressair^®^)                             Twice daily              Moderate-to-severe COPD (post-bronchodilator FEV~1~/FVC \<0.7; FEV~1~ ≥30% and \<80% predicted)                                              63.2          51.1       54.9                  53.3                           53.3                                       5
  Donohue et al (2016)[@b37-copd-12-3469]     NCT01437540                                                  Randomized, double-blind, parallel-group, active-controlled                                                    52                          590                           Aclidinium/formoterol 400/12 µg           Dry powder inhaler (Genuair/Pressair)                                   Twice daily              Moderate-to-severe COPD (post-bronchodilator FEV~1~/FVC \<0.7; FEV~1~ ≥30% and \<80% predicted)                                              64.3          55.1       45.4                  51.8                           51.2                                       4
  Singh et al (2014)[@b38-copd-12-3469]       NCT01462942                                                  Multicenter, randomized, double-blind, parallel-group, active- and placebo-controlled                          24                          1,348                         Aclidinium/formoterol 400/12 µg           Dry powder inhaler (Genuair/Pressair)                                   Twice daily              Moderate-to-severe COPD (post-bronchodilator FEV~1~/FVC \<0.7; FEV~1~ ≥30% and \<80% predicted)                                              63.2          67.6       47.3                  \>10                           54.3                                       4
  D'Urzo et al (2014)[@b39-copd-12-3469]      NCT01437397                                                  Multicentre, randomized, double-blind, placebo-controlled                                                      24                          1,389                         Aclidinium/formoterol 400/12 µg           Dry powder inhaler (Genuair/Pressair)                                   Twice daily              Moderate-to-severe stable COPD (post-bronchodilator FEV~1~/FVC \<0.7; FEV~1~ ≥30% and \<80% predicted)                                       64.1          53.3       51.7                  52.5                           53.7                                       3
  Mahler et al (2015)[@b40-copd-12-3469]      NCT01727141, NCT01712516                                     Identical, multicenter, randomized, double-blind, parallel-group, placebo- and active-controlled               12                          2,040                         Glycopyrronium/indacaterol 15.6/27.5 µg   Dry powder inhaler (Neohaler^®^)                                        Twice daily              Stable COPD (post-bronchodilator FEV~1~/FVC \<0.7; FEV~1~ ≥30% and \<80% predicted)                                                          63.5          64.8       52.2                  \>10                           54.6                                       5
  Watz et al (2016)[@b41-copd-12-3469]        NCT01996319                                                  Multicenter, randomized, double-blind, placebo-controlled, crossover                                           3                           193                           Glycopyrronium/indacaterol 50/110 µg      NA                                                                      Once daily               Moderate-to-severe stable COPD (post-bronchodilator FEV~1~/FVC \<0.7; FEV~1~ 40%--80% predicted)                                             62.8          65.5       56.7                  47.5                           61.6                                       4
  Buhl et al (2015)[@b44-copd-12-3469]        NCT01120717                                                  Multicenter, randomized, double-blind, placebo-controlled, parallel-group, dummy                               52                          338                           Glycopyrronium/indacaterol 50/110 µg      Dry powder inhaler (NA)                                                 Once daily               Moderate-to-severe COPD (post-bronchodilator FEV~1~/FVC \<0.7; FEV~1~ ≥30% and \<80% predicted)                                              62.7          76.9       49.2                  41.1                           53.3                                       5
  Bateman et al (2013)[@b42-copd-12-3469]     NCT01202188                                                  Multicenter, randomized, double-blind, parallel-group, placebo- and active-controlled                          26                          1,179                         Glycopyrronium/indacaterol 50/110 µg      Dry powder inhaler (Breezhaler^®^)                                      Once daily               Moderate-to-severe stable COPD (post-bronchodilator FEV~1~/FVC \<0.7; FEV~1~ ≥30% and \<80% predicted)                                       64.0          77.2       40.0                  \>10                           55.2                                       4
  Wedzicha et al (2013)[@b43-copd-12-3469]    NCT01120691                                                  Multicenter, randomized, double-blind, parallel-group                                                          64                          1,469                         Glycopyrronium/indacaterol 50/110 µg      Dry powder inhaler (Breezhaler)                                         Once daily               Severe-to-very severe COPD (post-bronchodilator FEV~1~/FVC \<0.7; FEV~1~ \<50% predicted)                                                    63.3          75.0       36.6                  \>10                           37.2                                       5
  O'Donnell et al (2017)[@b45-copd-12-3469]   NCT01533922, NCT01533935                                     Replicate, randomized, double-blind, placebo-controlled, incomplete-crossover                                  6                           450                           Tiotropium/olodaterol 5/5 µg              Soft mist inhaler (Respimat^®^)                                         Once daily               COPD (post-bronchodilator FEV~1~/FVC \<0.7; FEV~1~ ≥30% and \<80% predicted)                                                                 61.7          71.2       39.1                  45.8                           52.0                                       3
  Ichinose et al (2017)[@b46-copd-12-3469]    NCT01536262                                                  Multicenter, randomized, double-blind, parallel-group                                                          52                          82                            Tiotropium/olodaterol 5/5 µg              Soft mist inhaler (Respimat)                                            Once daily               Moderate-to-very severe COPD (post-bronchodilator FEV~1~/FVC \<0.7; FEV~1~ \<80% predicted)                                                  69.8          95.2       28.1                  60.3                           59.4                                       4
  Troosters et al (2016)[@b47-copd-12-3469]   NCT02085161                                                  Randomized, partially double-blind, placebo-controlled, parallel-group                                         12                          227                           Tiotropium/olodaterol 5/5 µg              Soft mist inhaler (Respimat)                                            Once daily               COPD (post-bronchodilator FEV~1~/FVC \<0.7; FEV~1~ ≥30% and \<80% predicted)                                                                 64.8          68.3       NA                    \>10                           NA                                         4
  Beeh et al (2015)[@b48-copd-12-3469]        NCT01559116                                                  Multicenter randomized, double-blind, placebo-controlled, incomplete-crossover                                 6                           139                           Tiotropium/olodaterol 5/5 µg              Soft mist inhaler (Respimat)                                            Once daily               COPD (post-bronchodilator FEV~1~/FVC \<0.7; FEV~1~ \<80% predicted)[\#](#tfn1-copd-12-3469){ref-type="table-fn"}                             61.1          58.9       62.6                  NA                             54.0                                       3
  Buhl et al (2015)[@b49-copd-12-3469]        NCT01431274, NCT01431287                                     Multicenter, multinational, replicate, randomized, double-blind, parallel-group, active-controlled, five-arm   52                          3,100                         Tiotropium/olodaterol 5/5 µg              Soft mist inhaler (Respimat)                                            Once daily               Moderate-to-very severe COPD (post-bronchodilator FEV~1~/FVC \<0.7; and FEV~1~ \<80% predicted)                                              64.0          72.9       37.0                  \>10                           50.0                                       3
  Singh et al (2015)[@b80-copd-12-3469]       NCT01964352, NCT02006732                                     Multinational, replicate, randomized, double-blind, placebo-controlled, parallel group                         12                          1,217                         Tiotropium/olodaterol 5/5 µg              Soft mist inhaler (Respimat)                                            Once daily               Moderate-to-severe COPD (post-bronchodilator FEV~1~/FVC \<0.7; FEV~1~ ≥30% and \<80% predicted)                                              64.8          61.2       47.7                  \>10                           55.1                                       3
  Donohue et al (2013)[@b51-copd-12-3469]     NCT01313650                                                  Multicenter, randomized, double-blind, parallel-group, placebo-controlled                                      24                          1,532                         Umeclidinium/vilanterol 62.5/25 µg        Dry powder inhaler (NA)                                                 Once daily               COPD (post-bronchodilator FEV~1~/FVC \<0.7; FEV~1~ ≤70% predicted)                                                                           63.3          70.7       48.2                  46.0                           47.6                                       4
  Decramer et al (2014)[@b52-copd-12-3469]    NCT01316900                                                  Multicenter, randomized, double-blind, parallel-group, double-dummy                                            24                          421                           Umeclidinium/vilanterol 62.5/25 µg        Dry powder inhaler (Ellipta^®^)                                         Once daily               COPD (categories B or D)                                                                                                                     63.7          67.4       44.3                  45.4                           47.3                                       5
  Siler et al (2016)[@b53-copd-12-3469]       NCT02152605                                                  Multicenter, randomized, double-blind, placebo-controlled, parallel-group                                      12                          496                           Umeclidinium/vilanterol 62.5/25 µg        Dry powder inhaler (Ellipta)                                            Once daily               COPD (pre- and post-albuterol \[salbutamol\] FEV~1~/FVC \<0.7; post-albuterol FEV~1~ ≤70% predicted)                                         63.4          59         53.5                  38.6                           47.5                                       4
  Donohue et al (2016)[@b6-copd-12-3469]      NCT01716520                                                  Multicenter, randomized, double-blind, three-way, complete block cross-over                                    2                           173                           Umeclidinium/vilanterol 62.5/25 µg        Dry powder inhaler (Ellipta)                                            Once daily               Moderate-to-severe COPD (post-bronchodilator FEV~1~/FVC \<0.7; FEV~1~ ≤70% predicted)                                                        63.2          70         55                    41.3                           47.8                                       3
  Zheng et al (2015)[@b54-copd-12-3469]       NCT01636713                                                  Multicenter, randomized, double-blind, placebo-controlled, parallel-group                                      24                          387                           Umeclidinium/vilanterol 62.5/25 µg        Dry powder inhaler (NA)                                                 Once daily               COPD (postalbuterol FEV~1~/FVC \<0.7; postalbuterol FEV~1~ ≤70% predicted; dyspnea score ≥2)                                                 64.2          93         31.5                  37.4                           NA                                         4
  Maltais et al (2014)[@b55-copd-12-3469]     NCT01323660, NCT01328444                                     Multicenter, randomized, placebo-controlled, parallel-group                                                    12                          832                           Umeclidinium/vilanterol 62.5/25 µg        Dry powder inhaler (Ellipta)                                            Once daily               Moderate-to-severe stable COPD (post-bronchodilator FEV~1~/FVC \<0.7; FEV~1~ \>35% and \<70% predicted)                                      62.0          56.4       62.0                  48.1                           51.3                                       4
  Martinez et al (2017)[@b56-copd-12-3469]    NCT01854645, NCT01854658                                     Multicenter, randomized, double-blind, placebo-controlled, parallel-group                                      24                          3,259                         Glycopyrronium°/formoterol 14.4/9.6 µg    Pressurised metered dose inhaler (Co-Suspension™ Delivery Technology)   Twice daily              Moderate-to-very severe COPD (post-bronchodilator FEV~1~/FVC \<0.7; \<80% predicted and ≥750 mL if FEV~1~ \<30% of predicted normal value)   62.9          55.4       53.8                  51.2                           51.5                                       4
  Hanania et al (2017)[@b57-copd-12-3469]     NCT01970878                                                  Multicenter, randomized, double-blind, parallel-group, active-controlled                                       28                          2,816                         Glycopyrronium°/formoterol 14.4/9.6 µg    Pressurised metered dose inhaler (Co-Suspension Delivery Technology)    Twice daily              Moderate-to-very severe COPD (post-bronchodilator FEV~1~/FVC \<0.7; \<80% predicted and ≥750 mL if FEV~1~ \<30% of predicted normal value)   62.8          55.3       54.0                  51.0                           43.1                                       4

**Notes:**

In German sites only, FEV~1~ ≥30%. °Equivalent to glycopyrrolate 18 µg.

**Abbreviations:** FEV~1~, forced expiratory volume in 1 second; FVC, forced vital capacity; NA, not available.

###### 

Pooled analysis of cardiovascular SAEs extracted from the [ClinicalTrials.gov](http://ClinicalTrials.gov) repository database and grouped by frequency in agreement with the EMA guideline[@b81-copd-12-3469]

  Cardiovascular SAEs                    LABA/LAMA FDCs   LABAs   LAMAs   Placebo   Cardiovascular SAEs                     LABA/LAMA FDCs   LABAs   LAMAs   Placebo
  -------------------------------------- ---------------- ------- ------- --------- --------------------------------------- ---------------- ------- ------- ---------
  Acute coronary syndrome                \+               \+      \+      ND        Extrasystoles                           \+               ND      ND      ND
  Acute myocardial infarction            ++               ++      ++      ++        Femoral artery occlusion                \+               ND      ND      ND
  Angina pectoris                        ++               ++      ++      ++        Hypertension                            \+               ++      ++      ++
  Angina unstable                        \+               \+      \+      ++        Hypertensive crisis                     ND               \+      \+      ND
  Aortic aneurysm                        \+               ++      \+      ND        Hypertensive emergency                  \+               ND      ND      ND
  Aortic aneurysm rupture                \+               ND      ND      ND        Hypotension                             \+               ++      ND      \+
  Aortic dissection                      ND               ND      \+      ND        Iliac artery stenosis                   \+               ND      ND      ND
  Aortic stenosis                        ND               \+      \+      \+        Intermittent claudication               ND               \+      \+      ND
  Arrhythmia                             ND               ND      ND      \+        Ischemic cardiomyopathy                 \+               ND      \+      \+
  Arterial disorder                      ND               \+      ND      ND        Left ventricular dysfunction            \+               ND      ND      \+
  Arterial occlusive disease             \+               \+      ND      ND        Leriche syndrome                        ND               \+      ND      ND
  Arterial stenosis                      ND               ND      \+      ND        Malignant hypertension                  \+               ND      ND      ND
  Arteriosclerosis                       \+               ND      ND      ND        Mitral valve stenosis                   ND               \+      ND      ND
  Arteriosclerosis coronary artery       \+               \+      \+      \+        Myocardial infarction                   ++               \+      ++      ++
  Atrial fibrillation                    ++               ++      ++      ++        Myocardial ischemia                     ++               ND      \+      ++
  Atrial flutter                         \+               ND      ++      ND        Palpitations                            ND               ND      \+      ND
  Atrial tachycardia                     \+               ND      ND      ND        Pericardial effusion                    ND               ND      \+      ND
  Atrioventricular block                 ND               \+      ND      ND        Pericarditis                            ND               ND      \+      ND
  Atrioventricular block complete        ND               ND      \+      \+        Peripheral arterial occlusive disease   \+               \+      \+      ND
  Atrioventricular block second degree   ND               \+      \+      ND        Peripheral artery aneurysm              ND               \+      \+      ND
  Bradycardia                            \+               ND      ++      \+        Peripheral artery stenosis              \+               ND      ND      ND
  Bundle branch block left               ND               \+      ND      ND        Peripheral artery thrombosis            ND               \+      ND      ND
  Cardiac arrest                         ++               ++      ++      ++        Peripheral ischemia                     \+               \+      ND      \+
  Cardiac disorder                       \+               ND      ND      ND        Peripheral vascular disorder            ++               ++      ND      ND
  Cardiac failure                        \+               ++      ++      ++        Phlebitis deep                          \+               ND      ND      ND
  Cardiac failure acute                  \+               \+      \+      ND        Right ventricular failure               ND               ND      \+      \+
  Cardiac failure chronic                \+               ND      ND      ND        Shock                                   ND               \+      ND      ND
  Cardiac failure congestive             ++               \+      ++      ND        Shock hemorrhagic                       \+               ND      ND      ND
  Cardio-respiratory arrest              ++               \+      ++      ND        Sick sinus syndrome                     ND               ND      \+      \+
  Cardiogenic shock                      \+               ND      ND      ND        Sinus tachycardia                       \+               ND      ND      ND
  Cardiomyopathy                         ND               ND      \+      \+        Supraventricular extrasystoles          ND               \+      ND      ND
  Cardiopulmonary failure                \+               ND      \+      ND        Supraventricular tachycardia            \+               \+      \+      \+
  Circulatory collapse                   ND               ND      \+      ND        Tachycardia                             ND               ND      \+      ND
  Cor pulmonale                          ND               ND      \+      ND        Thrombophlebitis                        ND               \+      ND      ND
  Cor pulmonale chronic                  \+               ND      ND      ND        Thrombophlebitis superficial            \+               ND      ND      ND
  Coronary artery disease                ++               ++      ++      ++        Thrombosis                              \+               ND      ND      ND
  Coronary artery occlusion              \+               ND      \+      ND        Torsade de pointes                      ND               \+      ND      ND
  Coronary artery stenosis               \+               ND      ND      ND        Ventricular extrasystoles               ND               ND      ND      \+
  Death                                  ++               ++      ++      ++        Ventricular fibrillation                ND               \+      ND      ND
  Deep vein thrombosis                   ++               \+      \+      \+        Ventricular tachycardia                 \+               \+      ND      ND
  Essential hypertension                 \+               ND      \+      ND                                                                                 

**Notes:** ++: uncommon (≥1/1,000 to \<1/100); +: rare (≥1/10,000 to \<1/1,000).

**Abbreviations:** EMA, European Medicine Agency; FDCs, fixed-dose combinations; LABA, long-acting β~2~-agonist; LAMA, long-acting muscarinic antagonist; ND, not detectable (frequency not known); SAEs, serious adverse events.

###### 

Safety profile of LABA/LAMA FDCs according to SUCRA analysis

  Treatment       SUCRA value (%)
  --------------- -----------------
  A/F 400/12      86.00
  T/O 5/5         75.67
  Placebo         49.67
  U/V 62.5/25     47.33
  G/F 14.4/9.6    39.00
  G/I 15.6/27.5   37.00
  G/I 50/110      15.00

**Abbreviations:** A, aclidinium; F, formoterol; FDCs, fixed-dose combinations; G, glycopyrronium; I, indacaterol; LABA, long-acting β~2~-agonist; LAMA, long-acting muscarinic antagonist; O, olodaterol; SUCRA, surface under the cumulative ranking curve; T, tiotropium; U, umeclidinium; V, vilanterol.
